The Chemo pharmaceutical group has just announced that it has acquired a stake in the US company Babyscripts, a virtual care platform for women during pregnancy, with the aim of helping it to consolidate its presence The United States and boost its expansion in Europe, starting with Spain. Together with the Chemo Group, Ysios Capital, a Spanish investment management company in the life sciences sector has led a funding round of 5.5 million euros which, in addition to the pharmaceutical multinational, has been joined by strategic investors such as CG Health Ventures, Aurora Health Care Ventures, and P5 Health Ventures.
The pharmaceutical multinational Chemo Group has just announced that it is opening two new plants that will produce injectable medicines. With these new facilities, the company now has a total of six plants in this country, employing more than 1,600 people between all of its work centres. The new plants, Universal Farma (Azuqueca de Henares, Guadalajara) with over 8,000 m2, and Farmalan (Villaquilambre, León) with 3,600 m2, have been prepared for the manufacture and final packaging of injectable medicines and are equipped with the sector's latest technology.
The pharmaceutical group Chemo has just launched a programme to help implement innovative health projects and to boost projects that are already up and running. With the name #ChemoStart, it is looking for start-ups that specialise in innovative solutions for patients, predictive analytics, biosensors or genomics, amongst others. For this, they have launched a microsite that allows researchers and entrepreneurs who wish to register their projects easily and participate in this initiative.
Exeltis Spain, a company that belongs to the Chemo Group, has acquired Juste's Pharma Unit in an operation that includes the sourcing, research, manufacture (through third parties), promotion and sale of pharmaceutical products for Gynaecology, the Central Nervous System and Primary Care, featuring drugs used to treat insomnia, depression and epilepsy. In the words of Exeltis's General Manager in Spain and Portugal, Alberto Fábregas: “The aim of this operation is to strengthen and increase the company's range of products, and to consolidate Exeltis's presence in the Iberian market, by incorporating the expertise and professionals of Juste's Pharma Unit”.
As a business adhering to the Responsible Care programme, Chemo Group has recently been authorised to use the CSR-Corporate Social Responsibility branding after fulfilling all the necessary requirements. This stamp guarantees Chemo Group’s commitment to Corporate Social Responsibility. The initiative aims to provide companies within this programme with visible recognition that certifies their commitment to CSR policies.
With more than 22 years of implementation in Spain, Responsible Care is the international voluntary initiative of the chemical sector for the continuous improvement of Safety, Health and Environmental Protection in all its operations, in accordance with the principles of Sustainable Development and The CSR. Currently more than 60% of Spanish chemical production is carried out in companies affiliated with Responsible Care.
Chemo Group has received one of the best business practices awards from KPMG and El Confidencial in the Internationalisation category, in which companies that allocate part of their resources to enter new markets abroad compete to search for new business opportunities. Our company has a strong commitment to internationalisation and the diversification of its investments. Thanks to this strategy, it is currently operating in 40 countries.
The Spanish plant Química Sintética, located in Alcalá de Henares, has once again set an example with its solidarity. This year's project was the same as last year's and it consisted of sending the metal closures from raw material containers to a metal recycler to raise funds. With these funds and the contributions of the employee, they were able to triple the number of snacks they donated to the Red Cross this year, donating over 830 snacks to the Corredor del Henares Red Cross for socially excluded children.
At the end of last year, Exeltis in Spain started a new phase full of enthusiasm and expectation. The new sales force met in Madrid for two weeks to learn and find out all about the Exeltis philosophy and its programme of excellence. Led by its director in Spain, Alberto Fábregas, and accompanied by Leandro Sigman, chairman of Chemo Group and Nick Haggar, CEO of Chemo Group, the forty new delegates of Exeltis prepared to make our brand a benchmark in Women's Health, with innovation as its banner and a clear commitment to serving both professionals and patients. From the outset, Exeltis has had a clear protagonist: science. We were fortunate to have with us prestigious gynaecologists who gave us their views on what is currently needed in gynaecology and in women's health education.
Santander played host to the 2016-2020 Child Friendly Cities Seal awards ceremony, which took place alongside the 8th UNICEF Best Practices, Child Rights and Municipal Policy awards ceremonies. It also included renewal of the Citation of Excellence certification for some twelve Child Friendly Cities. In total, the 2016 event saw more than 50 institutions, councils, cultural associations, primary and secondary schools, and foundations receive awards.
The multinational pharmaceutical Grupo Chemo, together with its Liconsa plant, located in Azuqueca de Henares, has just received one of the Business Excellence Awards 2016 from the CEOE Guadalajara for the category of "Highest recruitment" in the area. The awards, given out each year by the association from the Alcarria region, will be held on 12 November with the aim of highlighting some of the most outstanding companies over the past year.